Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af Ustekinumab hos pædiatriske deltagere med moderat til svær aktiv Crohns sygdom (UNITI Jr)

2. juli 2026 opdateret af: Janssen Research & Development, LLC

Et fase 3-studie af Ustekinumabs effektivitet, sikkerhed og farmakokinetik som åben intravenøs induktionsbehandling efterfulgt af randomiseret dobbeltblind subkutan Ustekinumab-vedligeholdelse hos pædiatriske deltagere med moderat til svær aktiv Crohns sygdom

Formålet med denne undersøgelse er at evaluere effektiviteten af ​​ustekinumab-dosering til at inducere klinisk remission (Global) og til at opretholde klinisk remission (US); at evaluere sikkerhedsprofilen og ustekinumab eksponering (farmakokinetik [PK]) hos pædiatriske deltagere med moderat til svær aktiv Crohns sygdom.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

101

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Brussels, Belgien, 1200
        • Cliniques Universitaires Saint Luc
      • Brussels, Belgien, 1020
        • Universitair Kinderziekenhuis Koningin Fabiola
      • Ghent, Belgien, 9000
        • UZ Gent
      • Jette, Belgien, 1090
        • UZ Brussel
      • Leuven, Belgien, 3000
        • UZ Leuven
      • Birmingham, Det Forenede Kongerige, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Det Forenede Kongerige, BS2 8BJ
        • University Hospitals Bristol and Weston NHS Foundation Trust
      • Cambridge, Det Forenede Kongerige, CB2 0QQ
        • Cambridge University Hospitals NHS Foundation Trust
      • Edinburgh, Det Forenede Kongerige, EH16 4TJ
        • Royal Hospital for Children and Young People
      • London, Det Forenede Kongerige, E1 2AT
        • Royal London Hospital
    • Delaware
      • Wilmington, Delaware, Forenede Stater, 19803
        • Nemours DuPont Hospital for Children
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30342
        • Children's Center for Digestive Health Care
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Mayo Clinic
    • New Jersey
      • Morristown, New Jersey, Forenede Stater, 07962
        • Morristown Memorial Hospital
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28207
        • Levine Childrens at Atrium Health
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Penn State Hershey Children's Hospital
    • Texas
      • Fort Worth, Texas, Forenede Stater, 76104
        • Cook Childrens Medical Center
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Pediatric Specialists Of Virginia
      • Be’er Ya‘aqov, Israel, 70300
        • Yitzhak Shamir Medical Center
      • Haifa, Israel, 34362
        • Carmel Medical Center
      • Jerusalem, Israel, 9103102
        • Shaare Zedek Medical Center
      • Petah Tikva, Israel, 4920235
        • Schneider Children's Medical Center
      • Bunkyō City, Japan, 113 8431
        • Juntendo University Hospital
      • Gunma, Japan, 371-0034
        • Gunma University Hospital
      • Ikoma, Japan, 630-0293
        • Kindai University Nara Hospital
      • Kurume, Japan, 830-0011
        • Kurume University Hospital
      • Saitama Shi, Japan, 330-8777
        • Saitama Childrens Medical Center
      • Sendai, Japan, 989-3126
        • Miyagi Children's Hospital
      • Setagaya Ku, Japan, 157 8535
        • National Center for Child Health and Development
      • Shimotsuke, Japan, 329-0498
        • Jichi Medical University Hospital
      • Tsu, Japan, 514 8507
        • Mie University Hospital
      • Gdansk, Polen, 80 803
        • Szpital im. M. Kopernika
      • Krakow, Polen, 30 663
        • Uniwersytecki Szpital Dzieciecy w Krakowie
      • Rzeszów, Polen, 35-302
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polen, 04 501
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polen, 04 730
        • Instytut Pomnik Centrum Zdrowia Dziecka
      • Kazan', Rusland, 420138
        • Kazan State Medical University
      • Moscow, Rusland, 119571
        • Russian National Research Medical University named after N.I.Pirogov
      • Nizhny Novgorod, Rusland, 603950
        • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
      • Yaroslavl, Rusland, 150032
        • Yaroslavl Regional Children's Clinical Hospital
      • Aachen, Tyskland, 52074
        • Universitätsklinikum Aachen
      • Berlin, Tyskland, 13353
        • Charite-Universitätsmedizin Berlin - Berlin
      • Essen, Tyskland, 45147
        • Universitätsklinikum Essen
      • Hanover, Tyskland, 30625
        • Medizinische Hochschule Hannover
      • Munich, Tyskland, 80337
        • Dr. von Haunersches Kinderspital
      • Regensburg, Tyskland, 93049
        • KUNO Klinik St. Hedwig
      • Ulm, Tyskland, 89075
        • Universitätsklinikum Ulm
      • Budapest, Ungarn, 1083
        • Semmelweis Egyetem
      • Debrecen, Ungarn, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Miskolc, Ungarn, 3526
        • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
      • Nyíregyháza, Ungarn, 4400
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház
      • Szeged, Ungarn, 6720
        • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

2 år til 17 år (Barn)

Tager imod sunde frivillige

Ingen

Beskrivelse

Inklusionskriterier:

  • Har Crohns sygdom eller fistulerende Crohns sygdom med aktiv colitis, ileitis eller ileocolitis, bekræftet på et hvilket som helst tidspunkt i fortiden ved endoskopi og histologi
  • Skal have moderat til svær aktiv Crohns sygdom (som defineret ved en baseline Pædiatrisk Crohns sygdoms aktivitetsindeks [PCDAI]-score større end [>] 30); have ileokolonoskopi med tegn på aktiv Crohns sygdom defineret som tilstedeværelse af ulceration (som er lig med Simple Endoscopic Score for Crohns sygdom [SES-CD] score større end eller lig med [>=] 3) under screening i denne undersøgelse. Ileokolonoskopiproceduren skal finde sted inden for ca. 3 uger før administration af undersøgelsesintervention i uge 0 (induktionsperiode). En video-ileokolonoskopi optaget inden for 3 måneder forud for besøget i uge 0 (induktionsperiode) kan bruges i tilfælde af genscreening af en deltager, som har fået foretaget en ileokolonoskopi, men som ikke bestod den indledende screening af en anden årsag, fra sag til sag, efter konsultation med sponsor. Hvis der ikke er mulighed for at vurdere sårdannelse på grund af forsnævring eller utilstrækkelig tarmforberedelse, kan mindst et af følgende kriterier anvendes i stedet: et unormalt C-reaktivt protein (CRP) (> 0,3 milligram pr. deciliter [mg/dL] eller 3,0 milligram pr. liter [mg/L] ved screening) eller; fækal calprotectin på >= 250 milligram pr. kilogram [mg/kg] eller >= 250 mikrogram pr. gram [mcg/g] ved screening
  • Hvis du modtager enteral ernæring, skal du have været på en stabil kur i mindst 2 uger før induktion uge 0 (uge I-0)
  • Kvinder i den fødedygtige alder skal have en negativ, meget følsom uringraviditetstest ved screening og i uge I-0 før indgivelse af undersøgelsesintervention

Ekskluderingskriterier:

  • Har komplikationer til Crohns sygdom, såsom symptomatiske forsnævringer eller stenose, kort tarmsyndrom eller enhver anden manifestation, der kan forventes at kræve kirurgi, som kan udelukke brugen af ​​PCDAI til at vurdere respons på terapi eller muligvis vil forvirre evnen til at vurdere effekt af behandling med ustekinumab
  • Har en historie med latent eller aktiv granulomatøs infektion, histoplasmose eller coccidioidomycosis, eller har haft en ikke-tuberkuløs mykobakteriel infektion før screening
  • Tilstedeværelse eller historie af enhver malignitet, herunder tilstedeværelse eller historie af lymfoproliferativ sygdom, herunder lymfom, eller tegn og symptomer, der tyder på mulig lymfoproliferativ sygdom, såsom lymfadenopati af usædvanlig størrelse eller placering (eksempel knuder i den bagerste trekant af halsen, infraclavicular, epitrochleær, eller periortiske områder) og monoklonal gammopati af ubestemt betydning eller klinisk signifikant hepatomegali eller splenomegali
  • Har en historie med moderat eller svær progressiv eller ukontrolleret lever- eller nyreinsufficiens; eller betydelige hjerte-, vaskulære, pulmonale, gastrointestinale, endokrine, neurologiske, hæmatologiske, psykiatriske (herunder suicidalitet) eller metaboliske forstyrrelser
  • Modtaget en undersøgelsesintervention, inklusive eventuelle undersøgelsesvacciner eller brugt et invasivt undersøgelsesmedicinsk udstyr inden for 3 måneder før den planlagte første dosis af undersøgelsesintervention eller er i øjeblikket tilmeldt en undersøgelsesundersøgelse; modtagelse af en undersøgelsesvaccine for Coronavirus Disease 2019 (COVID-19) er ikke et automatisk udelukkelseskriterium

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Åbent Ustekinumab Intravenøs (IV): Induktionsperiode
Alle deltagere vil modtage en enkelt intravenøs administration af ustekinumab ved induktionsuge 0 (I-0) baseret på kropsoverfladeareal (BSA) (milligram pr. kvadratmeter [mg/m^2]) eller vægtdelt induktionsdosis (milligram pr. kilogram [mg/kg]).
Ustekinumab vil blive administreret intravenøst ​​i induktionsperioden og subkutant i vedligeholdelsesperioden.
Eksperimentel: Ustekinumab Subkutan (SC) hver 8. uge (q8w): Vedligeholdelsesperiode
Deltagerne vil modtage SC-administration af ustekinumab q8w baseret på BSA (mg/m^2) eller vægtdelt induktionsdosis (mg/kg) ved vedligeholdelsesuger (uger M)-0, M-8, M-16, M-24 , M 32 og M-40 og matchende placebo i uge M-12 og M-36 for at opretholde blinden.
Ustekinumab vil blive administreret intravenøst ​​i induktionsperioden og subkutant i vedligeholdelsesperioden.
Matchende placebo vil blive administreret som subkutan injektion.
Eksperimentel: Ustekinumab SC hver 12. uge (q12w): Vedligeholdelsesperiode
Deltagerne vil modtage SC-administration af ustekinumab q12w baseret på BSA (mg/m^2) eller vægtdelt induktionsdosis (mg/kg) i uge M-0, M-12, M-24, M-36 og matchende placebo kl. Uger M-8, M-16, M-32 og M-40 for at vedligeholde blinden.
Ustekinumab vil blive administreret intravenøst ​​i induktionsperioden og subkutant i vedligeholdelsesperioden.
Matchende placebo vil blive administreret som subkutan injektion.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
Tidsramme: Induction Week 8 (Week I-8)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score =5. For albumin level, the maximum score = 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Induction Week 8 (Week I-8)
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
Tidsramme: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TESAEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Number of participants with AEs leading to discontinuation of study intervention were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported. It included hemoglobin (Hb). Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where atleast one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters were reported. It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB). Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where at least one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
Tidsramme: Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
Serum ustekinumab concentrations were reported.
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
Tidsramme: Induction Week 6 (Week I-6)
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10. The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was calculated only when >=3 of the 6 components were available.
Induction Week 6 (Week I-6)
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
Tidsramme: Induction Week 8
Assessment of response in children with Crohn's disease was evaluated using the PCDAI. Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations. Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality). For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
Induction Week 8
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
Tidsramme: Induction Week 6
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10. The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was only calculated when >=3 of the 6 components were available.
Induction Week 6
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
Tidsramme: Maintenance Period Week 8 (Study Week 16)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Period Week 8 (Study Week 16)
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
Tidsramme: Maintenance Week 8 (Study Week 16)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 8 (Study Week 16)
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
Tidsramme: Maintenance Week 44 (Study Week 52)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
Tidsramme: Maintenance Week 44 (Study Week 52)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Tidsramme: Maintenance Period Week 44 (Study Week 52)
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Period Week 44 (Study Week 52)
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
Tidsramme: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. april 2021

Primær færdiggørelse (Faktiske)

28. november 2024

Studieafslutning (Faktiske)

3. marts 2025

Datoer for studieregistrering

Først indsendt

14. december 2020

Først indsendt, der opfyldte QC-kriterier

14. december 2020

Først opslået (Faktiske)

17. december 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • CR108864
  • 2019-004225-24 (EudraCT nummer)
  • CNTO1275CRD3004 (Anden identifikator: Janssen Research & Development, LLC)
  • 2023-504978-38-00 (Registry Identifier: EUCT number)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Datadelingspolitikken for Janssen Pharmaceutical Companies of Johnson & Johnson er tilgængelig på www.janssen.com/clinical-trials/transparency. Som nævnt på dette websted kan anmodninger om adgang til undersøgelsesdataene indsendes gennem Yale Open Data Access (YODA) projektwebsted på yoda.yale.edu

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner